Life Science News

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB: KOMOF) (FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce it's now being carried in 4 out of 7 western Whole Foods Market locations

Whole Foods Market, Inc. is an American multinational supermarketchain headquartered in Austin, Texas, which sells organic foods and products free from hydrogenated fats and artificial colors, flavors, and preservatives. Whole Foods seeks out the finest natural and organic foods available, maintains the strictest quality standards in the industry, and has an unshakeable commitment to sustainable agriculture. Whole Foods has more than 500 retail and non-retail locations in the US, Canada and the United Kingdom. It has 14 retail locations in Canada, of which 7 are in British Columbia, and 7 are in Ontario. In 2017, Amazon purchased Whole Foods Market for USD$13.7 Billion.

"Adding Whole Foods to our distribution network is a huge accomplishment for Komo and testament to the high quality of our products," says Komo CEO William White. "We are so pleased with the growth in the number of retail stores that are selling Komo products. We have to thank our sales broker, Cornerstone Sales, our distributors, and our dedicated team for this growth. We are very excited about continuing to share the love of plant-based foods through our wholesale expansion"

Komo can now be found on the shelves at Whole Foods Cambie, North Burnaby, Victoria, and North Vancouver.

Komo has a distribution network covering all provinces in Canada, including BRR Logistics, TransCold Distribution and Nationwide Natural Foods. Komo significantly scaled up its production capacity through a co-manufacturing arrangement late last year, setting up Komo for nationwide expansion. Komo is also available in select IGA, Fresh Market, as well as all Choices Markets, all Nesters Market locations, Fairway Markets and Nature's Fare locations. Komo is now also expanding to the United States.

About Komo

Komo Plant Based Foods Inc. is a premium plant-based food company that develops, manufactures and sells a variety of plant-based frozen meals that are always hearty, satisfying, and made with wholesome ingredients. At Komo, our mission is to help make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. We believe plant-based eating is the future and - Change can start with a single biteTM. Our experienced plant-based innovation and development team recreates vegan versions of traditionally cheesy and meaty classics, with 100% plants. Komo's products are sold direct-to-consumer through our eCommerce website and a distribution network of online and brick and mortar grocery, convenience and natural retailer channels. Our operating subsidiary Komo Comfort Foods launched in 2021 with our flagship products: plant-based Lasagna, Shepherd's Pie and Chickenless Pot Pie and has recently launched a new line - Komo Plant-Based Meal HelpersTM - versatile meal starters to allow the creation of many dishes at home. All of our products are 100% plant-based, made with wholesome ingredients, free from preservatives, and frozen for freshness. Freezing products is a natural and effective way of keeping food products for longer without having to use any preservatives. Komo's meals have a 1-year frozen shelf life. Komo also sells hot ready-to-eat meals in Metro Vancouver through Uber Eats and Skip the Dishes.

Learn more at: www.komocomfortfoods.com and follow on Instagram: @komocomfortfoods

For further information, please contact:

William White, President & CEO, Komo Plant Based Foods Inc.
will@komoeats.com
1-866-969-0882

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or Komo's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Komo's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, Komo's product development plans, its ability to launch its products on food delivery apps, its ability to retain key personnel, its revenues, and its expectation as to the acceptance of its products by retailer stores and consumers constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. Komo disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

SOURCE: Komo Plant Based Foods Inc.



View source version on accesswire.com:
https://www.accesswire.com/697150/Komo-Plant-Based-Foods-Launches-in-Whole-Foods-Market-Retail-Locations-in-Western-Canada

News Provided by ACCESSWIRE via QuoteMedia

YUM:CC
Komo Plant-Based Foods

Komo Plant-Based Foods


Keep reading...Show less
Komo Plant Based Foods Inc. Establishes US Cold Storage Partnership

Komo Plant Based Foods Inc. Establishes US Cold Storage Partnership

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce it will be partnering with HLC Distributing as a third-party logistics (3PL) Warehouse for the U.S

"We are thrilled to work with Komo foods as they look to expand into the US market. They're an innovative company that understands the plant-based segment," said Alec Hendren, Vice President of HLC Distributing (HLC). "As a cold storage and logistics provider, we are excited to help provide the resources needed to get great products out into the market. It's the right fit for both companies and I look forward to building the relationship as we both grow."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Grows Distribution Across Quebec, Ontario, and Maritimes

Komo Plant Based Foods Grows Distribution Across Quebec, Ontario, and Maritimes

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB:KOMOF) (FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that Horizon Nature is now carrying all Komo frozen plant-based products for distribution, with a focus on Quebec and the Maritimes with a growing market in Ontario

Horizon Nature is a full service distributor to natural, independent and grocery banners. Founded in 2003, the company is still a Quebec family owned business today. Operating from a vast and modern distribution centre in St-Léonard, Horizon Nature offers a wide variety of local, national and global brands supported by an experienced sales team. As a supplier to Metro, Provigo, Tau and Avril, they offer a range of products spanning from fresh to dry grocery and frozen, with an emphasis on healthy whole foods as well as products across various dietary needs, whether gluten free or vegan ingredients and meals.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Shares Canadian Retail Update

Komo Plant Based Foods Shares Canadian Retail Update

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB:KOMOF) (FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce it's now being carried in a total of 240 distribution points across Canada; 39 of which are in Eastern Canada

According to a 2020 Statista Report there are 2.3 million vegetarians in Canada and an additional 850,000 classified themselves as vegan. Research conducted by the Angus Reid Institute (Canadian non-profit independent research organization) has found that 1 in 5 Canadians (22%) who regularly eat meat would like to reduce the amount of meat they consume. In eastern Canada, which has a population of 14 million, people spend an average of $10,418 per year on food. Source: https://www.statista.com/statistics/567888/average-annual-household-expenditures-in-ontario-canada/

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant-Based Foods Awarded Best New Vegan Product of Expo West 2022

Komo Plant-Based Foods Awarded Best New Vegan Product of Expo West 2022

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo" or the "Company") a premium plant-based food company, made its first in-person, U.S. trade show debut at Natural Products Expo West (NPEW), at the Anaheim Convention Center in Anaheim, California. At the conference, Komo took home the VegNews Best of Show Award 2022 for Best New Vegan Product of the show

Founded in 2000, VegNews is one of the most established vegan news sources in the world. It produces four magazines annually, reaching 3.6 million people monthly across print, digital, and social media.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant-Based Foods Monthly Revenue Hits All-Time High

Komo Plant-Based Foods Monthly Revenue Hits All-Time High

The Company recorded over $100k in revenue for the month of February alone, which overshoots the Company's previous all-time high in December of 2021 by 46%

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo" or the "Company") a premium plant-based food company, is pleased to announce that it's February revenue catapulted to over $100k, a full 46% increase over Komo's previous best month of sales in December 2021

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Lawsuits Filed Against Vrt, Abbv And Ibm - Jakubowitz Law Pursues Shareholders Claims

Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below

Vertiv Holdings Co (NYSE:VRT)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VLTA, AUPH and BKKT

The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery

Volta Inc. (NYSE:VLTA)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report

Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at: https:www.fcaaids.orginformphilanthropic-support-to-address-hiv-aids is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes 2020 funding data (the most recent year available) revealing that Gilead's philanthropic support wholly drove the increase of private HIV and AIDS philanthropic funding representing 38% of all HIV funding and driving a majority of the increases in funding across all issues, populations and geographies. Gilead is also recognized in the report as the number one funder in the U.S. and the number three funder internationally. The report indicates that, "Private HIV and AIDS philanthropic funding to the U.S. rose for the seventh year in a row, totaling over $321 million in 2020, a dramatic 52% ($109 million) increase from 2019."

In addition to being recognized as the number one funder both overall and in the U.S., Gilead was also recognized as the number one funder across a range of categories, including:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Gummy Project

Potent Ventures Announces New Distribution Partnership with Dean's Dairy and Specialty Foods in Preparation for Launch of the Gummy Project

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is pleased to announce that the Company has entered into a new distribution partnership with Dean's Dairy & Specialty Foods ("Dean's").

Dean's distributes premium all-natural & organic products to grocers, cafes, and eateries in Vancouver, the Lower Mainland, and Vancouver Island. Dean's supports a network of +500 unique customer locations across the current 37 retail brands, and delivers 6 days a week with trucks that are meticulously maintained to ensure the freshest on-time delivery.

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, NTRA and AXSM

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

ABBVie Inc. (NYSE:ABBV)
Class Period: April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

ABBV DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important June 6, 2022 Deadline Reminder for AbbVie, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against ABBVie, Inc. (ABBVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period").

CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK ON THEFOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r

TO VIEW OUR COMPLAINT, PLEASE CLICK HERE

LEAD PLAINTIFF DEADLINE:JUNE 6, 2022
CLASS PERIOD: APRIL 30, 2021 through AUGUST 31, 2021

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com

Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

ABBVIE'S ALLEGED MISCONDUCT

AbbVie is one of the world's largest pharmaceutical companies. The company's revenues will come under significant pressure in the coming years when its best-selling drug, Humira, will lose patent protection in 2023. Accordingly, AbbVie's future revenue and earnings depend in large part on its ability to develop new sources of revenue to offset Humira's lost sales. Rinvoq-an anti-inflammatory drug manufactured by AbbVie and used to treat rheumatoid arthritis (RA) and other diseases by inhibiting Janus kinase (JAK) enzymes-was touted as one such drug. Rinvoq was initially approved in the United States to treat only moderate to severe RA. However, AbbVie was actively pursuing additional treatment indications and, in 2020, asked the U.S. Food and Drug Administration (FDA) to approve Rinvoq for the treatment of several other diseases.

As is relevant here, Rinvoq is similar to other JAK inhibitor drugs, including Xeljanz, manufactured by Pfizer Inc. When the FDA approved Xeljanz in 2012 for the treatment of RA, it required an additional safety trial to evaluate Xeljanz's risk of triggering certain serious side effects. Beginning in February 2019, the FDA repeatedly warned the public that the safety trial indicated that Xeljanz's use could lead to serious heart-related issue, cancer, and other adverse events. Notwithstanding the similarities between Rinvoq and Xeljanz, during the Class Period, Defendants assured investors that Rinvoq was far safer than Xeljanz and not subject to the same regulatory risks.

However, investors began to learn the truth about Rinvoq's significant risks on June 25, 2021, when AbbVie revealed that the FDA was delaying its review of expanded treatment applications for Rinvoq due to the safety concerns associated with Xeljanz. On this news, the price of AbbVie common stock declined $1.76 per share, or approximately 1.5%, from a close of $114.74 per share on June 24, 2021, to close at $112.98 per share on June 25, 2021.

Then, on September 1, 2021, the FDA announced that final results from the Xeljanz safety trial established an increased risk of serious adverse events, even with low doses of Xeljanz. As a result, the FDA determined that it would require new and updated warnings for Xeljanz and Rinvoq because Rinvoq "share[s] similar mechanisms of action with Xeljanz" and "may have similar risks as seen in the Xeljanz safety trial." The FDA also indicated that it would further limit approved indications for Rinvoq as a result of these safety concerns. On this news, the price of AbbVie common stock declined $8.51 per share, or more than 7%, from a close of $120.78 per share on August 31, 2021, to close at $112.27 per share on September 1, 2021.

After the Class Period, on December 3, 2021, AbbVie announced that the FDA had updated Rinvoq's label to require additional safety warnings and limit marketing of Rinvoq to only its use after treatment with other drugs has failed. On January 11, 2022, Defendants admitted that these changes to Rinvoq's label would negatively impact sales, forcing the Company to reduce its long-term guidance for Rinvoq's sales in 2025.

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company's business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis, As a result of the Defendants' wrongful acts and omissions, and the significant decline in the market value of AbbVie's securities, AbbVie investors have suffered significant damages.

WHAT CAN I DO?

AbbVieinvestors may, no later than June 6, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages AbbVie investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE

WHO CAN BE A LEAD PLAINTIFF?

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/124414

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×